Novavax Inc (NVAX) Stock Price

NVAXStock

$9.44+13.01%52W

Market Cap$1.56B

P/E2.98x

PEG Ratio1.32

Div yield—

Beta2.53

NVAX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.29%

Price vs S&P 500 (4W)17.17%

PEG Ratio1.32

VGM Score50.68

P/E Ratio (Annual)2.98x

Book Value / Share (Quarterly)$0.23

P/TBV (Annual)11.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-17.24%

Cash Flow / Share (Quarterly)$-0.26

Price vs S&P 500 (YTD)19.89%

Gross Margin (TTM)79.16%

Net Profit Margin (TTM)-59.87%

EPS (TTM)$-1.54

10-Day Avg Trading Volume4.83M

EPS Excl Extra (TTM)$-1.54

Revenue Growth (5Y)18.76%

EPS (Annual)$2.54

ROI (Annual)-38.19%

Gross Margin (Annual)93.50%

Net Profit Margin (5Y Avg)-45.81%

Cash / Share (Quarterly)$4.36

P/E Basic Excl Extra (TTM)3.80x

Revenue Growth QoQ (YoY)-76.30%

P/E Normalized (Annual)2.98x

ROA (Last FY)-12.02%

Revenue Growth TTM (YoY)-61.64%

EBITD / Share (TTM)$-1.45

ROE (5Y Avg)-43.51%

Operating Margin (TTM)-63.52%

Cash Flow / Share (Annual)$-0.63

P/B Ratio34.90x

P/B Ratio (Quarterly)27.12x

Net Income / Employee (Annual)$587,900

EV / Revenue (TTM)3.43x

Net Interest Coverage (TTM)20.61x

ROA (TTM)-22.75%

EV / EBITDA (TTM)3.14x

EPS Incl Extra (Annual)$2.54

Current Ratio (Annual)0.98x

Quick Ratio (Quarterly)2.23x

3-Month Avg Trading Volume4.50M

52-Week Price Return13.01%

P/E Incl Extra (TTM)3.80x

Revenue / Employee (TTM)$552,500

Tangible BV / Share (Quarterly)$0.78

P/S Ratio (Annual)1.17x

Asset Turnover (Annual)0.44x

52-Week High$11.97

Operating Margin (5Y Avg)-47.20%

EPS Excl Extra (Annual)$2.54

CapEx CAGR (5Y)-36.67%

Tangible BV CAGR (5Y)66.48%

26-Week Price Return1.96%

Quick Ratio (Annual)0.92x

13-Week Price Return-1.34%

Total Debt / Equity (Annual)0.75x

Current Ratio (Quarterly)2.33x

Enterprise Value$1.42B

Revenue / Share Growth (5Y)-4.70%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)-0.67%

Revenue / Employee (Annual)$1,500,000

Inventory Turnover (Annual)8.00x

Pretax Margin (Annual)39.36%

Cash / Share (Annual)$5.77

3-Month Return Std Dev61.62%

Gross Margin (5Y Avg)66.92%

Net Income / Employee (TTM)$-330,700

ROE (Last FY)-66.69%

Net Interest Coverage (Annual)-14.53x

EPS Basic Excl Extra (Annual)$2.54

P/FCF (TTM)12.41x

Receivables Turnover (TTM)3.38x

Total Debt / Equity (Quarterly)6.07x

EPS Incl Extra (TTM)$-1.54

Receivables Turnover (Annual)5.18x

ROI (TTM)40.02%

P/S Ratio (TTM)3.17x

Pretax Margin (5Y Avg)-44.86%

Revenue / Share (Annual)$6.49

Tangible BV / Share (Annual)$8.75

Forward P/E77.23x

Price vs S&P 500 (52W)-5.30%

P/E Ratio (TTM)3.80x

Year-to-Date Return31.85%

5-Day Price Return11.73%

EPS Normalized (Annual)$2.54

ROA (5Y Avg)-33.11%

Net Profit Margin (Annual)39.19%

Month-to-Date Return21.04%

Cash Flow / Share (TTM)$-5.39

EBITD / Share (Annual)$2.61

Operating Margin (Annual)37.75%

LT Debt / Equity (Annual)0.51x

ROI (5Y Avg)-37.60%

P/E Excl Extra (TTM)3.80x

LT Debt / Equity (Quarterly)4.53x

EPS Basic Excl Extra (TTM)$-1.54

P/TBV (Quarterly)92.41x

P/B Ratio (Annual)11.32x

Inventory Turnover (TTM)8.52x

Pretax Margin (TTM)-59.28%

Book Value / Share (Annual)$8.83

Price vs S&P 500 (13W)-4.13%

Beta2.53x

P/FCF (Annual)4.95x

Revenue / Share (TTM)$2.51

ROE (TTM)283.08%

52-Week Low$6.20

vGradeB

gGradeD

mGradeC

vgmGradeC

NVAX Earnings Surprise History

Q2 250.62est. -0.08

Q3 25-1.25est. -1.17

Q4 250.11est. -0.49

Q1 26-0.06est. -0.24

Q2 26-0.32est. -0.38

NVAX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.67

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
NVAXNovavax Inc	B	D	C	$9.44
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Novavax Inc

Novavax Inc is a biotechnology company developing vaccines to prevent a broad range of human infectious diseases, with a focus on both established and emerging disease threats. The company conducts clinical-stage development of novel vaccine candidates, supported by its Swedish subsidiary's manufacturing operations. Its proprietary vaccine technology platform is designed for broad applicability across multiple infectious disease indications, with the majority of revenue generated from the United States.